查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球仿製藥合同製造市場：市場規模按藥物類型、產品、給藥途徑、應用、地區、競爭戰略、細分市場預測至2032
市場調查報告書
商品編碼
1182440

全球仿製藥合同製造市場：市場規模按藥物類型、產品、給藥途徑、應用、地區、競爭戰略、細分市場預測至2032

Generic Pharmaceuticals Contract Manufacturing Market Size- By Drug Type, By Product, By Route of Administration, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 244 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

到 2032 年，全球仿製藥合同製造市場預計將達到 1214.2 億美元，複合年增長率為 6.04%。

外包在節省成本和時間方面的優勢正在推動行業發展。 治療慢性病的藥物成本高，增加了對具有成本效益的仿製藥的需求。 該部門有許多重要的公司，預計將對發展產生重大影響。

本報告考察了全球仿製藥合同製造市場，並提供了有關市場動態、市場變量和前景、競爭格局、按藥物類型、產品、給藥途徑、應用和地區、公司概況等進行的市場分析的信息。 .

內容

第一章介紹

  • 調查範圍
  • 市場細分分析

第二章研究方法論

  • 調查數據來源
  • 市場規模估計
  • 數據三角測量

第 3 章執行摘要

第四章市場動態

  • 分析驅動因素、制約因素、機遇和挑戰
    • 司機
    • 約束因素
    • 機會
    • 任務
  • COVID-19 對全球仿製藥合同製造市場的影響

第五章市場變數與展望

  • SWOT 分析
    • 強度
    • 弱點
    • 機會
    • 威脅
  • PESTEL 分析
    • 政治形勢
    • 經濟狀況
    • 社交情況
    • 技術
    • 環境狀況
    • 法律狀況
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手之間的敵對關係
  • 熱圖分析

第六章競爭格局

  • 仿製藥全球代工的分銷基地、銷售區域和產品類型
  • 全球通用合同製造領域的併購、合作夥伴關係、產品發布和協作

第 7 章全球仿製藥合同製造市場：按藥物類型分類（2019-2032，百萬美元）

  • 品牌
  • 沒有品牌

第 8 章全球通用合同製造市場：按產品分類（2019-2032，百萬美元）

  • API
  • 醫藥

第 9 章全球通用合同製造市場：按管理途徑（2019-2032，百萬美元）

  • 口語
  • 腸外
  • 本地
  • 其他

第 10 章全球通用合同製造市場：按應用（2019-2032，百萬美元）

  • 抗凝劑
  • 抗糖尿病藥
  • 心血管
  • HIV 抗病毒藥物
  • 免疫學
  • 神經學
  • 腫瘤學
  • 疼痛
  • 呼吸科
  • 其他

第 11 章全球通用合同製造市場：按地區（2019-2032，百萬美元）

  • 市場規模/市場份額：按地區（2019-2025 年）
  • 各地區的市場規模/市場份額（2026 年至 2032 年）
  • 亞太地區
    • 澳大利亞
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 歐洲
    • 法國
    • 德國
    • 意大利
    • 西班牙
    • 英國
    • 其他歐洲
  • 中東和非洲
    • 沙特阿拉伯王國
    • 阿拉伯聯合酋長國
    • 其他中東和非洲地區
  • 北美
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他拉丁美洲

第12章公司簡介

  • Acme Generics Pvt Ltd.
    • 公司簡介
    • 財務展望
    • 產品概述
    • 最近的發展
  • Alcami Corp. Inc.
  • Aurobindo Pharma
  • Cambrex Corp.
  • Catalent, Inc
  • Curia Global, Inc.
  • Jubilant Generics Ltd.
  • Metric Contract Services
  • Pfizer CentreOne
  • Recipharm Ab
  • Siegfried Holding AG
  • Syngene International Limited

第13章縮略語列表

第 14 章參考鏈接

第15章結論

第 16 章範圍

簡介目錄
Product Code: PHAR2215

Global Generic Pharmaceuticals Contract Manufacturing Market Overview:

According to SPER Market Research, the Global Generic Pharmaceuticals Contract Manufacturing Market is estimated to reach USD 121.42 billion by 2032 with a CAGR of 6.04%.

The industry's growth is being driven by the advantages of outsourcing in terms of cost and time savings. A generic medication is a prescription medication that shares the same chemical components as a medication that was first covered by a chemical patent. Following the expiration of the patents on the original medications, generic medications may be sold. Generics function as well in terms of the medical profile because the active chemical component is the same. The active pharmaceutical ingredient (API) in a generic medication is the same as that in the brand-name medication, but there may be differences in the manufacturing method, formulation, excipients, colour, taste, and packaging. Around the world, a sizable population is afflicted with chronic illnesses. For instance, according to the CDC, 6 out of 10 persons in the U.S. have at least one chronic condition, and 4 out of 10 have two or more. Long-term treatment is necessary for chronic diseases. The demand for cost-effective generic drugs for the treatment of chronic diseases is rising as a result of the high cost of pharmaceuticals. It is anticipated that the presence of numerous important firms in this area will have a substantial impact on its development.

Impact of COVID-19 on the Global Generic Pharmaceuticals Contract Manufacturing Market:

This is anticipated to boost the industry's expansion following the pandemic. The regulatory approval process for generic medications has improved. Advancements in this sector are anticipated to benefit the production of generic medications and, as a result, assist the expansion of the sector. The Japanese government is continually working to develop the nation's market for generic medications. The government is also urging medical institutions to promote the use of generic medications and is taking steps to increase the availability of generics in the nation. In the upcoming years, this is anticipated to enhance CMO operations for generic drugs. The amount spent globally on medications is also increasing. The region's growth is further supported by the increasing tendency of pharmaceutical businesses in the area to outsource non-core activities like manufacturing.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Type, By Product, By Route of Administration, By Application
  • Regions covered: Asia Pacific, Europe, Middle East and Africa,North America, Latin America
  • Companies Covered: Acme Generics Pvt Ltd., Alcami Corp. Inc., Aurobindo Pharma, Cambrex Corp., Catalent, Inc, Curia Global, Inc., Jubilant Generics Ltd., Metric Contract Services, Pfizer CentreOne, Recipharm Ab, Siegfried Holding AG, Syngene International Limited

Global Generic Pharmaceuticals Contract Manufacturing Market Segmentation:

  • By Drug Type: Based on the Drug Type, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Branded, Unbranded.
  • By Product: Based on the Product, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; API, Drug Product.
  • By Route of Administration: Based on the Route of Administration, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Oral, Parenteral, Topical, Others.
  • By Application: Based on the Application, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Anticoagulants, Antidiabetic, Cardiovascular, HIV antivirals, Immunology, Neurology, Oncology, Pain, Respiratory, Others.
  • By Region: The lowest CAGR is anticipated in Asia Pacific over the projected period, mostly as a result of the region's inexpensive manufacturing of generic medications.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Generic Pharmaceuticals Contract Manufacturing Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4.Heat map analysis

6. Competitive Landscape

  • 6.1. Global Generic Pharmaceuticals Contract Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Generic Pharmaceuticals Contract Manufacturing

7. Global Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type, 2019-2032 (USD Million)

  • 7.1. Branded
  • 7.2. Unbranded

8. Global Generic Pharmaceuticals Contract Manufacturing Market, By Product, 2019-2032 (USD Million)

  • 8.1. API
  • 8.2. Drug Product

9. Global Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration, 2019-2032 (USD Million)

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical
  • 9.4. Others

10. Global Generic Pharmaceuticals Contract Manufacturing Market, By Application, 2019-2032 (USD Million)

  • 10.1. Anticoagulants
  • 10.2. Antidiabetic
  • 10.3. Cardiovascular
  • 10.4. HIV antivirals
  • 10.5. Immunology
  • 10.6. Neurology
  • 10.7. Oncology
  • 10.8. Pain
  • 10.9. Respiratory
  • 10.10. Others

11. Global Generic Pharmaceuticals Contract Manufacturing Market, By Region, 2019-2032 (USD Million)

  • 11.1. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2019-2025)
  • 11.2. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2026-2032)
  • 11.3. Asia-Pacific
    • 11.3.1. Australia
    • 11.3.2. China
    • 11.3.3. India
    • 11.3.4. Japan
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4 Europe
    • 11.4.1 France
    • 11.4.2 Germany
    • 11.4.3 Italy
    • 11.4.4 Spain
    • 11.4.5 United Kingdom
    • 11.4.6 Rest of Europe
  • 11.5 Middle East & Africa
    • 11.5.1 Kingdom of Saudi Arabia
    • 11.5.2 United Arab Emirates
    • 11.5.3 Rest of Middle East & Africa
  • 11.6 North America
    • 11.6.1 Canada
    • 11.6.2 Mexico
    • 11.6.3 United States
  • 11.7 Latin America
    • 11.7.1 Argentina
    • 11.7.2 Brazil
    • 11.7.3 Rest of Latin America

12. Company Profiles

  • 12.1 Acme Generics Pvt Ltd.
    • 12.1.1 Company details
    • 12.1.2 Financial outlook
    • 12.1.3 Product summary
    • 12.1.4 Recent developments
  • 12.2 Alcami Corp. Inc.
    • 12.2.1 Company details
    • 12.2.2 Financial outlook
    • 12.2.3 Product summary
    • 12.2.4 Recent developments
  • 12.3 Aurobindo Pharma
    • 12.3.1 Company details
    • 12.3.2 Financial outlook
    • 12.3.3 Product summary
    • 12.3.4 Recent developments
  • 12.4 Cambrex Corp.
    • 12.4.1 Company details
    • 12.4.2 Financial outlook
    • 12.4.3 Product summary
    • 12.4.4 Recent developments
  • 12.5 Catalent, Inc
    • 12.5.1 Company details
    • 12.5.2 Financial outlook
    • 12.5.3 Product summary
    • 12.5.4 Recent developments
  • 12.6 Curia Global, Inc.
    • 12.6.1 Company details
    • 12.6.2 Financial outlook
    • 12.6.3 Product summary
    • 12.6.4 Recent developments
  • 12.7 Jubilant Generics Ltd.
    • 12.7.1 Company details
    • 12.7.2 Financial outlook
    • 12.7.3 Product summary
    • 12.7.4 Recent developments
  • 12.8 Metric Contract Services
    • 12.8.1 Company details
    • 12.8.2 Financial outlook
    • 12.8.3 Product summary
    • 12.8.4 Recent developments
  • 12.9 Pfizer CentreOne
    • 12.9.1 Company details
    • 12.9.2 Financial outlook
    • 12.9.3 Product summary
    • 12.9.4 Recent developments
  • 12.10 Recipharm Ab
    • 12.10.1 Company details
    • 12.10.2 Financial outlook
    • 12.10.3 Product summary
    • 12.10.4 Recent developments
  • 12.11 Siegfried Holding AG
    • 12.11.1 Company details
    • 12.11.2 Financial outlook
    • 12.11.3 Product summary
    • 12.11.4 Recent developments
  • 12.12 Syngene International Limited
    • 12.12.1 Company details
    • 12.12.2 Financial outlook
    • 12.12.3 Product summary
    • 12.12.4 Recent developments

13. List of Abbreviations

14. Reference Links

15. Conclusion

16. Research Scope